How should mirtazapine be dosed, administered, monitored, and tapered, and what are its contraindications and side effects?

Mirtazapine Dosing, Administration, Monitoring, and Safety

Initial Dosing and Titration

Start mirtazapine at 15 mg once daily at bedtime, then increase to 30 mg/day after 1–2 weeks if tolerated, with further titration to 45 mg/day based on clinical response. 1, 2, 3

• The recommended starting dose is 15 mg/day administered as a single bedtime dose to leverage its prominent sedative effect 2, 3
• Therapeutic dosing typically ranges from 15–45 mg/day, with some patients requiring up to 60–70 mg/day 1
• Dose-related steady-state plasma concentrations show linear pharmacokinetics: 15 mg yields ~7 ng/mL, 30 mg yields ~18 ng/mL, 45 mg yields ~28 ng/mL, and 60 mg yields ~38 ng/mL 1
• A therapeutic plasma concentration threshold of ≥30 ng/mL is associated with response; non-responders with levels below this threshold may benefit from dose escalation 4
• Allow 6–8 weeks at therapeutic doses before declaring treatment failure, as approximately 50% of eventual remitters achieve remission between weeks 6 and 14 5

Administration and Pharmacokinetics

• Mirtazapine is rapidly absorbed with peak plasma concentrations reached within 2 hours; absolute bioavailability is ~50% due to first-pass metabolism 6
• Food has minimal effect on absorption extent, so it can be taken with or without meals 6
• The elimination half-life ranges from 20–40 hours, with steady state achieved in 4–6 days, supporting once-daily dosing 6
• Mirtazapine exhibits enantioselective pharmacokinetics, with the R-enantiomer having a longer half-life (18 hours) than the S-enantiomer (10 hours) 6

Dose Adjustments for Drug Interactions and Special Populations

Reduce the mirtazapine dose by approximately 50% when co-administered with strong CYP3A inhibitors (e.g., itraconazole, ritonavir, nefazodone) or cimetidine; conversely, increase the dose when strong CYP3A inducers (e.g., carbamazepine, phenytoin, rifampin) are used. 2, 6

• Carbamazepine causes a 60% decrease in mirtazapine plasma concentrations, necessitating dose increases 6
• Paroxetine and fluoxetine cause modest increases (17% and 32%, respectively) in mirtazapine levels but rarely require dose adjustment 6
• In patients with moderate renal or hepatic impairment, oral clearance decreases by ~30%; severe renal impairment decreases clearance by 50%, warranting lower starting doses and slower titration 6
• Females and elderly patients show higher plasma concentrations than males and younger adults, requiring careful dose titration 6

Critical Safety Monitoring

Monitor patients weekly during the first month of treatment for emergence of suicidal ideation, agitation, irritability, unusual behavioral changes, and worsening depression, particularly within 1–2 weeks of any dose change. 5, 7, 2

• The FDA boxed warning emphasizes increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults, especially early in treatment 2
• Reassess within 1–2 weeks after any medication change to detect mood destabilization or emergent suicidal ideation 5

Agranulocytosis and Hematologic Monitoring

• Instruct patients to immediately report fever, chills, sore throat, mucous membrane ulceration, or flu-like symptoms, as mirtazapine carries a risk of agranulocytosis 2, 8
• Although rare, obtain a complete blood count if infection symptoms develop 5

Serotonin Syndrome Risk

• Mirtazapine is contraindicated with MAOIs (including linezolid and IV methylene blue) and should not be initiated within 14 days of stopping an MAOI due to serotonin syndrome risk 2
• Monitor for serotonin syndrome symptoms (agitation, confusion, tachycardia, hyperthermia, hyperreflexia, myoclonus) when combining with other serotonergic drugs (SSRIs, SNRIs, triptans, tramadol, fentanyl, St. John's Wort) 2

Cardiovascular and Metabolic Monitoring

• Mirtazapine may prolong the QTc interval; avoid concomitant use with other QTc-prolonging drugs and instruct patients to report palpitations, syncope, or lightheadedness 2
• Obtain baseline metabolic parameters (BMI, waist circumference, blood pressure, fasting glucose, fasting lipids) before initiating treatment 5
• Follow-up metabolic monitoring: BMI monthly for 3 months then quarterly; blood pressure, glucose, and lipids at 3 months and annually thereafter 5

Additional Laboratory Screening

• Check thyroid function (TSH, free T4), complete blood count, vitamin B12, and folate to exclude reversible contributors to depressive symptoms 5
• Perform urine drug screening to detect undisclosed substance use that may interfere with treatment 5

Common and Serious Adverse Effects

The most common adverse effects are somnolence (23%), dry mouth (25%), increased appetite (11%), and weight gain (10%), which are typically mild, transient, and decrease over time despite dose increases. 8

• Sedation is prominent and may impair judgment, thinking, and motor skills; caution patients against operating machinery or driving until they know how mirtazapine affects them 2, 3
• Avoid alcohol and benzodiazepines, as concomitant use increases cognitive and motor impairment 2
• Mirtazapine has virtually no anticholinergic, adrenergic, or typical SSRI side effects (e.g., nausea, diarrhea, sexual dysfunction, insomnia) 8
• Sedative effects appear temporary and do not require plasma concentration control when standard doses are used 4

Serious Adverse Reactions

• Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), Stevens-Johnson syndrome, bullous dermatitis, erythema multiforme, and toxic epidermal necrolysis have been reported; mirtazapine is contraindicated in patients with known hypersensitivity 2
• Advise patients to report fever, rash, swollen lymph nodes, or other signs of DRESS immediately 2
• Mirtazapine may cause mild pupillary dilation, potentially triggering angle-closure glaucoma in susceptible individuals; consider prophylactic iridectomy in at-risk patients 2

Activation of Mania/Hypomania

• Monitor for signs of manic activation (increased energy, decreased need for sleep, racing thoughts, impulsivity) and report to the healthcare provider 2

Discontinuation and Tapering

Never abruptly discontinue mirtazapine; taper gradually over several weeks to minimize discontinuation syndrome, which can include panic attacks, palpitations, dyspnea, dizziness, nausea, and anguish. 2, 9

• A case report documented severe, recurrent panic attacks occurring every 1–2 hours for 5 days after abrupt cessation of 30 mg/day mirtazapine after 10 weeks of treatment 9
• Symptoms resolved only after reinstitution of mirtazapine, illustrating the need for progressive tapering even after medium-duration therapy 9
• Discuss any tapering regimen with the patient and adjust the schedule based on emergence of withdrawal symptoms 2

Contraindications

• Concurrent use or use within 14 days of MAOIs (including linezolid and IV methylene blue) 2
• Known hypersensitivity to mirtazapine or any excipient, including history of severe skin reactions (DRESS, Stevens-Johnson syndrome, toxic epidermal necrolysis) 2

Overdose and Safety Profile

• Mirtazapine has a very low seizure-inducing potential (only one case in a patient with prior seizure history) and lacks cardiotoxic properties, allowing relative safety in overdose 8
• The only symptom observed in overdose cases (alone or in combination with other drugs) was excessive but transient somnolence that resolved spontaneously within hours 8
• Drop-out rates due to adverse events are significantly lower with mirtazapine (65%) compared to amitriptyline (87%) or placebo (76%) 8

Special Clinical Contexts

Augmentation Strategy for Treatment-Resistant Depression

• Mirtazapine can be used as an augmentation agent, though bupropion augmentation yields higher remission rates (~30%) and lower discontinuation rates (12.5% vs 20.6% with buspirone) 5, 10
• If partial response to current antidepressant exists, augmentation may be preferable to switching 10

Insomnia in Older Adults

• A recent randomized controlled trial (MIRAGE study) demonstrated that mirtazapine 7.5 mg significantly reduced insomnia severity (mean ISI change -6.5 vs -2.9 with placebo, p=0.003) in adults ≥65 years with chronic insomnia 11
• However, 6 participants in the mirtazapine group discontinued due to adverse events versus 1 in placebo, limiting its use in some older patients 11

Pregnancy and Lactation

• Advise patients to notify their physician if they become pregnant or intend to become pregnant; a pregnancy exposure registry monitors outcomes in women exposed to mirtazapine 2
• Advise breastfeeding patients to notify their physician, as mirtazapine is excreted in breast milk 2